A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01989676
Completed
The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280014 in combination with paclitaxel versus trastuzumab sourced from the European Union (trastuzumab-EU) with paclitaxel in female patients with HER2-positive, metastatic breast cancer in the first-line treatment setting. The hypothesis to be tested in this study is that the efficacy (ORR) of PF-05280014 is similar to trastuzumab-EU.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/07/2021
Locations: Cancer Center of Central Connecticut, Plainville, Connecticut +187 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
NCT00031694
Completed
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin-1 in treating patients who have locally advanced unresectable or metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin-1 may help paclitaxel kill more cancer cells by making tumor cells more sensitive to the drug.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/18/2021
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Register for Updates
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
NCT02413320
Completed
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
05/06/2021
Locations: University of Kansas Cancer Center - CRC, Fairway, Kansas +8 locations
Conditions: Triple-negative Breast Cancer
Register for Updates
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
NCT00580333
Completed
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer. Cisplatin is used to destroy cancer cells in many types of cancers, and has shown to be effective and have manageable side effects. Bevacizumab i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Breast Cancer
Register for Updates
Locally Advanced NSCLC Hyperfractionated RT
NCT03128008
Completed
This is a prospective phase II study designed to evaluate an accelerated and adaptive RT approach for locally-advanced non-small cell lung cancer (NSCLC). All eligible subjects will have an interim PET-CT during radiation therapy to determine the metabolic complete response rate. Radiation therapy will be given in an accelerated fashion (2 Gy/fraction, 6 fractions/week) with concurrent chemotherapy. Interim responses will be assessed using PERCIST criteria. Despite concurrent chemotherapy and r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2021
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Carcinoma, Non Small Cell Lung (NSCLC)
Register for Updates
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
NCT00542191
Terminated
This neoadjuvant chemotherapy protocol focusing on "triple-negative" breast cancers alone will gather a foundation of primary tumor and axillary lymph nodal response to primary chemotherapy and ongoing correlated disease-free (DFS) and overall survival (OS) outcome data. This comparative data can then be used in building subsequent trials.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/04/2021
Locations: Brody School of Medicine at East Carolina University, Greenville, North Carolina
Conditions: Breast Cancer
Register for Updates
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
NCT01220128
Terminated
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2021
Locations: GSK Investigational Site, Newark, Delaware +35 locations
Conditions: Neoplasms, Breast
Register for Updates
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
NCT00004067
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus trastuzumab is more effective than combination chemotherapy alone for treating breast cancer. PURPOSE: Th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2021
Locations: Comprehensive Cancer Institute, Huntsville, Alabama +148 locations
Conditions: Breast Cancer
Register for Updates
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
NCT00582205
Terminated
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
04/28/2021
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
Register for Updates
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer
NCT01507428
Unknown
This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans, to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor and cause less damage to healthy tissue.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2021
Locations: Stanford Cancer Institute Palo Alto, Palo Alto, California +30 locations
Conditions: Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Register for Updates
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
NCT00546156
Completed
Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with bevacizumab. Bevacizumab is an antibody which works differently from the way other chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors by binding... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Breast Cancer
Register for Updates
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
NCT02269293
Completed
The purpose of this study is to test the safety of the investigational drug, selinexor (KPT-330), in combination with carboplatin and paclitaxel chemotherapy, where paclitaxel will be given at two different dosing schedules and selinexor will be given at two different dosing schedules. Carboplatin and paclitaxel chemotherapy is a commonly used therapy for the treatment of advanced or recurrent ovarian, fallopian tube, primary peritoneal, or endometrial cancer. The investigators want to find out... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/22/2021
Locations: Memoral Sloan Kettering Monmouth, Middletown, New Jersey +2 locations
Conditions: Ovarian Cancer, Endometrial Cancer
Register for Updates